Imagine a child with a rare brain condition whose seizures simply won't stop, even with strong medicine. This project creates a high-quality, medical-grade cannabis oil that acts like a specialized key to calm the brain's electrical storms. It's designed to be safer and more effective than current options, which often cause bad side effects like extreme sleepiness.
Current antiepileptic drugs for Tuberous Sclerosis Complex are insufficient, with 60% of patients suffering from refractory epilepsy. Existing cannabis-based options are often criticized for high prices and adverse side effects like somnolence and behavioral disorders.
A medicinal full-spectrum cannabis sativa extract (YCJ-01) with a 20:1 CBD/THC ratio produced under GMP conditions.
If you are an orphan drug developer dealing with the lack of effective treatments for Tuberous Sclerosis Complex — this project developed YCJ-01 that targets refractory epilepsy with fewer side effects than current drugs.
If you are a pediatric neurology clinic dealing with 60% of TSC patients who have treatment-resistant seizures — this project developed a GMP-standard cannabis extract that improves patient quality of life.
If you are a cannabinoid research firm dealing with the lack of clinical evidence for full-spectrum extracts — this project developed a controlled 20:1 CBD to THC ratio drug produced under strict GMP conditions.
The project data does not provide specific pricing for YCJ-01, but it notes that existing approved treatments like Epidyolex have pricing that causes dissatisfaction among clinicians and caregivers.
Based on available project data, the drug is produced under controlled GMP (Good Manufacturing Practice) conditions, which is the standard for industrial pharmaceutical scaling.
Based on available project data, OILS4CURE SL is the developer and coordinator, but specific patent or licensing terms are not detailed in the provided text.
The project adheres to Good Clinical Practices (GCP) and Good Manufacturing Practices (GMP) to ensure the product is a medicinal-grade cannabis extract.
The project period runs from 2023-12-01 to 2026-08-31, suggesting the development and validation phase concludes in late 2026.
The project is led by a single Spanish SME, OILS4CURE SL, representing a 100% industry ratio. This lean structure suggests a fast-track commercialization path where the coordinator maintains full control over the IP and development of the YCJ-01 and YCJ-02 therapies.
Contact OILS4CURE SL in Spain regarding YCJ-01 development
Contact us to explore licensing opportunities for YCJ-01
